Viral Load

SAN FRANCISCO — Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, baseline suppressive therapies among adults with HIV.

Early combination ART initiation during primary HIV infection can lead to sustained virological suppression after switching to dolutegravir monotherapy, data from the EARLY-SIMPLIFIED study suggests.

A study of almost 4,000 people with HIV and sustained 2-year period of viral suppression found that they were unlikely to experience viral rebound over the next 2 years, supporting treatment as prevention as an HIV prevention strategy.

A monoclonal antibody was shown to speed the time to viral suppression in heavily treatment-experienced people with HIV compared with ART regimens that did not contain it, according to a study.

SEATTLE —SARS-CoV-2 viral loads were more than four times lower among participants in a phase 3 trial who received the diabetes drug metformin than among those who received placebo, according to findings presented at a medical conference.

SEATTLE — Doravirine was noninferior at maintaining viral suppression in people with HIV through 48 weeks when compared with bictegravir/emtricitabine/tenofovir alafenamide, as well as baseline ART.

Women with HIV who had greater cumulative viremia had an increased risk of multimorbidity and developing five vascular-related non-AIDS comorbidities, according to a recent study.

Cumulative viral load may be associated with incident hypertension among people with HIV, despite CVD risk factors possibly differing between health care systems, researchers found.

During a recent 5-year period, incident bacterial sexually transmitted infections increased among HIV-infected men who have sex with men regardless of virologic control, according to a recent study.

The investigational oral antiviral molnupiravir eliminated actively infectious SARS-CoV-2, improved self-reported outcomes and benefited immunocompromised patients with COVID-19, according to three separate analyses of the MOVe-OUT study.